Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride for hair loss lowers PSA levels, so PSA values need adjusting when screening for prostate cancer.

Incidental prostate cancer was found in 4.89% of patients undergoing surgery for benign prostatic hyperplasia.

Serenoa repens may help with prostate issues, but more research is needed to confirm its effectiveness.

Using finasteride and doxazosina together works better for treating benign prostatic hyperplasia than using just one.

Middle-aged and elderly men with BPH had higher hospitalization rates for COVID-19.

Anti-androgen therapy may boost immunity but increases injection site pain in vaccinated patients.

Women with androgenetic alopecia (hair loss) have normal prostate specific antigen levels but higher testosterone levels.

Hair loss linked to prostate enlargement; stress and family history important factors.

Different prostate cancer treatments have similar risks of secondary cancers and related mortality when considering patient age and smoking history.

E211 G>A gene linked to lower risk of severe prostate cancer and hair loss.

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

Herbal products for benign prostate hypertrophy need better quality checks to ensure safety and effectiveness.

Men with benign prostate hyperplasia have more meibomian gland loss and tear film problems.

More prostate biopsies increase the chance of finding cancers that may not need treatment.

DHT in the human prostate is produced through multiple pathways, not just from testosterone.

Medications have become the main treatment for enlarged prostate symptoms, replacing surgery and watchful waiting.

Finasteride may reduce prostate bleeding by lowering blood vessel growth factor levels and blood vessel density in certain prostate areas.

Wedelolactone selectively kills prostate cancer cells without harming normal cells.

Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.

Finasteride may reduce prostate cancer spread by lowering certain enzyme levels.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.

Finasteride effectively reduces prostate size and lowers surgery risk in men with benign prostatic hyperplasia.

The normal human prostate does not significantly affect blood DHT levels.

Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

New treatments for enlarged prostate are being developed, some of which may be more effective than current medications.

New treatments for enlarged prostate are being developed to be more effective and have fewer side effects.

Urban living may increase prostate cancer risk, while early sexual activity might reduce it.